Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 94, Issue 5, 1996, Pages 311-319

  Wieselgren, I M ^a,c   Lindstrom E ^a   Lindstrom L H ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c Ulleraker Hospital   (Sweden)

Author keywords

Longitudinal study; Prediction; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0029955078     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb09866.x     Document Type: Article

References (30)

1. CROW TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J 1980: 280: 66-68.
2. CROW TJ. The two-syndrome concept: origins and current status. Schizophr Bull 1985: 11: 471-486.
3. ANDREASEN NC. Positive and negative symptoms in schizophrenia: a critical evaluation. Schizophr Bull 1985: 11: 380-389.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
5. MCGLASHAN TH, FENTON WS. The positive-negative distinction in schizophrenia. Review of natural history validators. Arch Gen Psychiatry 1992: 49: 63-72.
6. BIEHI, H, MAURER K, SCHAUBERT C, KRUM B, JUNG E. Prediction of outcome and utilization of medical services in a prospective study of first onset schizophrenics: results of a prospective 5-year follow-up study. Eur Arch of Psychiatry Neurol Sci 1986: 236: 139-147.
7. MCCREADIE RG, WILES D, GRANT S et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989: 80: 597-602.
8. POGUE GM, HARROW M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 1985: 11: 427-439.
9. FENTON WS, MCGLASHAN TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991: 48: 978-986.
10. MUNK-JORGENSEN P, MORTENSEN PB. Schizophrenia: a 13-year follow-up. Diagnostic and psychopathological aspects. Acta Psychiatr Scand 1989: 79: 391-399.
11. KAY SR, SINGH MM. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. Arch Gen Psychiatry 1989: 46: 711-718.
12. BREIER A, SCHREIBER JL, DYER J, PICKAR D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome (published erratum appears in Arch Gen Psychiatry 1991: 48: 642). Arch Gen Psychiatry 1991: 48: 239-246.
13. Hwu H-G, TAN H, CHEN C-C, YEH L-L. Negative symptoms at discharge and outcome in schizophrenia. Br J Psychiatry 1995: 166: 61-67.
14. ANDREASEN NC, OLSON S. Negative versus positive schizophrenia: definition and and validation. Arch Gen Psychiatry 1982: 39: 789-794.
15. American Psychiatric Association. Diagnostical and statistical manual of mental disorders: DSM-III-R. Washington, DC: American Psychiatric Association, 1987.
16. WIESELGREN I-M, LINDSTRÖM LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, onset of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand 1995: 93: 9-19.
17. LINDSTRÖM EM, ÖHLUND LS, LINDSTRÖM LH, ÖHMAN A. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic in-patients. Psychiatry Res 1992: 42: 145-158.
18. ÅSBERG M, PERRIS C, SCHALLING D, SEDVALL G. The CPRS - development and applications of a psychiatric rating scale. Acta Psychiatr Scand 1978: 271: 5-27.
19. ANDREASEN NC. The scale for the assessment of negative symptoms (SANS). Iowa City, Iowa: University of Iowa, 1983.
20. LINDSTRÖM E, LINDSTRÖM LH. Negative symptomatology in a group of schizophrenic patients; a comparison between the Comprehensive Psychopathological Rating Scale (CPRS) and the Schedule for Assessment of Negative Symptoms (SANS). Eur Arch Psychiatr Clin Neurosci 1996: 246: 219-223.
21. STRAUSS JS, CARPENTER WT. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry 1972: 27: 739-746.
22. SAS Institute. SAS/STAT user's guide. Realeasev 6.03 edn. 1988: Cary, NC: SAS Institute, 1988.
23. CARPENTER WT, HEINRICHS DW, WAGMAN AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988: 145: 578-583.
24. MELTZER HY, BASTANI B, RAMIREZ L, MATSUBARA S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989: 238: 332-339.
25. KANE JM, HONIGFELD G, SINGER J, MELTZER HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988: 45: 789-796.
26. FENTON WS, MCGLASHAN TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992: 49: 179-184.
27. GOLDSTEIN JM, LINK BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988: 22: 141-155.
28. RING N, TANTAM D, MONTAGUE L, NEWBY D, BLACK D, MORRIS J. Gender differences in the incidence of definite schizophrenia and atypical psychosis - focus on negative symptoms of schizophrenia. Acta Psychiatr Scand 1991: 84: 489-496.
29. LINDSTRÖM E, VON KNORRING L. Principal component analysis of the Swedish version of the positive and negative syndrome scale for schizophrenia. Nord J Psychiatry 1993: 47: 257-263.
30. PERALTA V, CUESTA MJ, DE LEON J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994: 36: 726-736.